Zhuo Georgia Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhuo Georgia Chen has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Nabil F. Saba
Winship Cancer Institute Emory University Atlanta Georgia USA
43 shared publications - Yong Teng
Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA
23 shared publications - Chloe Shay
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory, University, Atlanta, Georgia
22 shared publications - Fan Yang
Winship Cancer Institute Emory University Atlanta Georgia USA
22 shared publications - Fanghui Chen
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, School of Medicine, Atlanta, Georgia
22 shared publications - Hancai Dan
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
22 shared publications
Latest Publications
- Open Access
- 30 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5269
Feasibility Assessment of Autologous Human Immune System (HIS) ImmunoGraft Platform Development Using Autologous Mobilized Peripheral Blood (MPB) CD34 Cells Derived from Adult HNSCC Patient
Humanized mice generated by hematopoietic stem cell (HSC) transplantation are limited by the immune system developed being allogeneic to the tumor. We have innovated a platform to reconstitute an autologous human immune system (HIS) in immunodeficient NOG-EXL mice from mobilized peripheral blood (MPB)-CD34 cells, along with PDX generated from the same patient’s tumor tissue. Patients consented under an IRB-approved protocol for tumor biopsy and HSC apheresis at Emory University. HSC collection included mobilization with G-CSF and plerixafor, immunomagnetic bead isolation with CliniMACS, and cryopreservation of CD34+ cells. PDX were established from biopsies or surgical specimens by passaging into immunodeficient mice. Irradiated NOG-EXL mice were engrafted with HSCs by intravenous transplantation of CD34+ HSC. Engraftment of human T cells, B cells, and myeloid cells in peripheral blood was assessed by serial flow cytometry of blood samples, with final assessment of immune components in spleen and bone marrow at 30 weeks. Twenty-eight PDX models were generated from 43 patients with HNSCC; 1 patient underwent apheresis. HSC engraftment in blood was observed in 100% of NOG-EXL mice at 8 weeks post-transplant, with 5–20% hCD45+ cells present in the periphery. B-cell development was predominant at early time points and declined over time. Human T-cell and subset development of CD4+ and CD8+ T cells were observed in blood from 15 weeks post-transplant. Strong development of the myeloid lineage (CD33+) was observed starting at 8 weeks and persisted throughout the study. These data demonstrate that mobilization and apheresis of HNSCC patients is technically and clinically feasible and may allow the establishment of autologous HIS-PDX mice.
- 30 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5269
Open AccessFeasibility Assessment of Autologous Human Immune System (HIS) ImmunoGraft Platform Development Using Autologous Mobilized Peripheral Blood (MPB) CD34 Cells Derived from Adult HNSCC Patient
Humanized mice generated by hematopoietic stem cell (HSC) transplantation are limited by the immune system developed being allogeneic to the tumor. We have innovated a platform to reconstitute an autologous human immune system (HIS) in immunodeficient NOG-EXL mice from mobilized peripheral blood (MPB)-CD34 cells, along with PDX generated from the same patient’s tumor tissue. Patients consented under an IRB-approved protocol for tumor biopsy and HSC apheresis at Emory University. HSC collection included mobilization with G-CSF and plerixafor, immunomagnetic bead isolation with CliniMACS, and cryopreservation of CD34+ cells. PDX were established from biopsies or surgical specimens by passaging into immunodeficient mice. Irradiated NOG-EXL mice were engrafted with HSCs by intravenous transplantation of CD34+ HSC. Engraftment of human T cells, B cells, and myeloid cells in peripheral blood was assessed by serial flow cytometry of blood samples, with final assessment of immune components in spleen and bone marrow at 30 weeks. Twenty-eight PDX models were generated from 43 patients with HNSCC; 1 patient underwent apheresis. HSC engraftment in blood was observed in 100% of NOG-EXL mice at 8 weeks post-transplant, with 5–20% hCD45+ cells present in the periphery. B-cell development was predominant at early time points and declined over time. Human T-cell and subset development of CD4+ and CD8+ T cells were observed in blood from 15 weeks post-transplant. Strong development of the myeloid lineage (CD33+) was observed starting at 8 weeks and persisted throughout the study. These data demonstrate that mobilization and apheresis of HNSCC patients is technically and clinically feasible and may allow the establishment of autologous HIS-PDX mice.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Effect of IR on viability of radioresistant and parental CAL27 and HN6 cells determined by alamarBlue assays on Day 5 after IR.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Effect of IR on viability of radioresistant and parental CAL27 and HN6 cells determined by alamarBlue assays on Day 5 after IR.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Radiotherapy plays an essential role in the treatment of head and neck squamous cell carcinoma (HNSCC), yet radioresistance remains a major barrier to therapeutic efficacy. A better understanding of the predominant pathways determining radiotherapy response could help develop mechanism-informed therapies to improve cancer management. Here we report that radioresistant HNSCC cells exhibit increased tumor aggressiveness. Using unbiased proteome profiler antibody arrays, we identify that upregulation of c-Met phosphorylation is one of the critical mechanisms for radioresistance in HNSCC cells. We further uncover that radioresistance-associated HNSCC aggressiveness is effectively exacerbated by c-Met but is suppressed by its genetic knockdown and pharmacologic inactivation. Mechanistically, the resulting upregulation of c-Met promotes elevated expression of plexin domain containing 2 (PLXDC2) through activating ERK1/2-ELK1 signaling, which in turn modulates cancer cell plasticity by epithelial–mesenchymal transition (EMT) induction and enrichment of the cancer stem cell (CSC) subpopulation, leading to resistance of HNSCC cells to radiotherapy. Depletion of PLXDC2 overcomes c-Met–mediated radioresistance through reversing the EMT progress and blunting the self-renewal capacity of CSCs. Therapeutically, the addition of SU11274, a selective and potent c-Met inhibitor, to radiation induces tumor shrinkage and limits tumor metastasis to lymph nodes in an orthotopic mouse model. Collectively, these significant findings not only demonstrate a novel mechanism underpinning radioresistance-associated aggressiveness but also provide a possible therapeutic strategy to target radioresistance in patients with HNSCC.Significance:This work provides novel insights into c-Met-PLXDC2 signaling in radioresistance-associated aggressiveness and suggests a new mechanism-informed therapeutic strategy to overcome failure of radiotherapy in patients with HNSCC.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Radiotherapy plays an essential role in the treatment of head and neck squamous cell carcinoma (HNSCC), yet radioresistance remains a major barrier to therapeutic efficacy. A better understanding of the predominant pathways determining radiotherapy response could help develop mechanism-informed therapies to improve cancer management. Here we report that radioresistant HNSCC cells exhibit increased tumor aggressiveness. Using unbiased proteome profiler antibody arrays, we identify that upregulation of c-Met phosphorylation is one of the critical mechanisms for radioresistance in HNSCC cells. We further uncover that radioresistance-associated HNSCC aggressiveness is effectively exacerbated by c-Met but is suppressed by its genetic knockdown and pharmacologic inactivation. Mechanistically, the resulting upregulation of c-Met promotes elevated expression of plexin domain containing 2 (PLXDC2) through activating ERK1/2-ELK1 signaling, which in turn modulates cancer cell plasticity by epithelial–mesenchymal transition (EMT) induction and enrichment of the cancer stem cell (CSC) subpopulation, leading to resistance of HNSCC cells to radiotherapy. Depletion of PLXDC2 overcomes c-Met–mediated radioresistance through reversing the EMT progress and blunting the self-renewal capacity of CSCs. Therapeutically, the addition of SU11274, a selective and potent c-Met inhibitor, to radiation induces tumor shrinkage and limits tumor metastasis to lymph nodes in an orthotopic mouse model. Collectively, these significant findings not only demonstrate a novel mechanism underpinning radioresistance-associated aggressiveness but also provide a possible therapeutic strategy to target radioresistance in patients with HNSCC.Significance:This work provides novel insights into c-Met-PLXDC2 signaling in radioresistance-associated aggressiveness and suggests a new mechanism-informed therapeutic strategy to overcome failure of radiotherapy in patients with HNSCC.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Elevated PLXDC2 expression in radioresistant HN6 cells is mediated by c-Met-activated ERK1/2-ELK signaling.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Elevated PLXDC2 expression in radioresistant HN6 cells is mediated by c-Met-activated ERK1/2-ELK signaling.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The putative ELK1 binding sites (the sequences are in red with indicated location) on the PLXDC2 promoter region upstream of the start codon for the full-length protein.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The putative ELK1 binding sites (the sequences are in red with indicated location) on the PLXDC2 promoter region upstream of the start codon for the full-length protein.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The correlation between the expression of ELK1 and PLXDC2 genes illustrated in scatter plot from the TCGA HPV(+) HNSCC cohort (n=98).
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The correlation between the expression of ELK1 and PLXDC2 genes illustrated in scatter plot from the TCGA HPV(+) HNSCC cohort (n=98).
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Validation the expression levels of top five most upregulated genes (identified from RNA-seq) in radioresistant CAL27 (A) and HN6 (B) cells using qRT-PCR. *p<0.05; **p<0.01.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Validation the expression levels of top five most upregulated genes (identified from RNA-seq) in radioresistant CAL27 (A) and HN6 (B) cells using qRT-PCR. *p<0.05; **p<0.01.
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Effect of PLXDC2 knockdown on colony formation of radioresistant CAL27 and HN6 cells determined on Day 12 following 4 Gy IR exposure
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Effect of PLXDC2 knockdown on colony formation of radioresistant CAL27 and HN6 cells determined on Day 12 following 4 Gy IR exposure
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The correlation between the expression of ELK1 and PLXDC2 genes illustrated in scatter plot from the TCGA HPV(+) HNSCC cohort (n=98).
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
The correlation between the expression of ELK1 and PLXDC2 genes illustrated in scatter plot from the TCGA HPV(+) HNSCC cohort (n=98).
- Open Access
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Inhibitory effect of three c-Met inhibitors on c-Met phosphorylation in CAL27 cells. CAL27 cells were treated with 2.5 µM SU11274, foretinib or crizotinib for 24 hours, followed by Western blotting analysis.
- 19 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer
Inhibitory effect of three c-Met inhibitors on c-Met phosphorylation in CAL27 cells. CAL27 cells were treated with 2.5 µM SU11274, foretinib or crizotinib for 24 hours, followed by Western blotting analysis.